"Neuroprotective Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
Descriptor ID |
D018696
|
MeSH Number(s) |
D27.505.696.706.548 D27.505.954.427.575
|
Concept/Terms |
Neuroprotective Agents- Neuroprotective Agents
- Agents, Neuroprotective
- Neuroprotectants
- Neuroprotective Drugs
- Drugs, Neuroprotective
Neuroprotective Effect- Neuroprotective Effect
- Effect, Neuroprotective
- Neuroprotective Effects
- Effects, Neuroprotective
|
Below are MeSH descriptors whose meaning is more general than "Neuroprotective Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuroprotective Agents".
This graph shows the total number of publications written about "Neuroprotective Agents" by people in this website by year, and whether "Neuroprotective Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 1 | 0 | 1 |
2010 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2020 | 1 | 0 | 1 |
2021 | 3 | 0 | 3 |
2023 | 3 | 0 | 3 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroprotective Agents" by people in Profiles.
-
Pentoxifylline protects memory performance in streptozotocin-induced diabetic rats. Brain Res. 2025 Jan 15; 1847:149319.
-
Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson's Disease. J Neuroimmune Pharmacol. 2023 Dec; 18(4):704-717.
-
Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial. J Neurotrauma. 2023 09; 40(17-18):1889-1906.
-
Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial. J Neurotrauma. 2023 09; 40(17-18):1878-1888.
-
4R-cembranoid protects neuronal cells from oxygen-glucose deprivation by modulating microglial cell activation. Brain Res Bull. 2022 02; 179:74-82.
-
1-Indanone and 1,3-indandione Derivatives as Ligands for Misfolded a-Synuclein Aggregates. ChemMedChem. 2022 01 19; 17(2):e202100611.
-
Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent. J Clin Pharmacol. 2021 09; 61(9):1232-1242.
-
Protective effect of propranolol and nadolol on social defeat-induced behavioral impairments in rats. Neurosci Lett. 2020 04 23; 725:134892.
-
Protective Effect of Tempol on Buthionine Sulfoximine-Induced Mitochondrial Impairment in Hippocampal Derived HT22 Cells. Oxid Med Cell Longev. 2016; 2016:5059043.
-
Pharmacology of riluzole in acute spinal cord injury. J Neurosurg Spine. 2012 Sep; 17(1 Suppl):129-40.